Can Biotechs Recover From Trump’s Strong Condemnation?

| January 13, 2017

article image
From Zacks: The pharma and biotech industry is a victim of concerns over increased regulatory scrutiny on high drug prices over the past two years. The worries cooled down after Trump’s victory, and gave biotech stocks a shot in the arm. But the trend has reversed again following Trump’s first press conference held earlier this week (read: ETFs & Stocks That Topped or Flopped After Trump Won). This is especially true as Trump criticized drugmakers by saying that they are “getting away with murder” by charging too much for their products. As Americans consume the most pharmaceutical drugs in the world, Trump pledged to initiate a bidding process for drug cost. The move, if enacted, would erode the profitability of the industry’s biggest players.

Spotlight

Premier Health Care Management

Family owned and operated since 1998, Premier Health Care Management has built a reputation of quality and excellence. We deliver post-acute and long-term care to those in need and currently operate 8 buildings across Cincinnati and Dayton. Our hand-selected staff has the education and expertise you’ve come to expect from the Premier name. We feel it is a privilege to celebrate the lives of your loved ones. Here at Premier, our family is honored to care for yours.

OTHER ARTICLES

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Spotlight

Premier Health Care Management

Family owned and operated since 1998, Premier Health Care Management has built a reputation of quality and excellence. We deliver post-acute and long-term care to those in need and currently operate 8 buildings across Cincinnati and Dayton. Our hand-selected staff has the education and expertise you’ve come to expect from the Premier name. We feel it is a privilege to celebrate the lives of your loved ones. Here at Premier, our family is honored to care for yours.

Events